@article{81ede4afda414ef9a16f1006d795ccb6,
title = "Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD",
author = "Laidlaw, {Tanya M.} and Joaquim Mullol and Chunpeng Fan and Donghui Zhang and Nikhil Amin and Asif Khan and Jingdong Chao and Mannent, {Leda P.}",
note = "Funding Information: This research was sponsored by Sanofi and Regeneron Pharmaceuticals (ClinicalTrials.gov Identifier: NCT01920893). Medical writing/editorial assistance provided by Sin?ad Holland, PhD, of Excerpta Medica, was funded by Sanofi Genzyme and Regeneron Pharmaceuticals. We thank Qunming Dong for his contribution. Funding Information: This research was sponsored by Sanofi and Regeneron Pharmaceuticals (ClinicalTrials.gov Identifier: NCT01920893). Medical writing/editorial assistance provided by Sin{\'e}ad Holland, PhD, of Excerpta Medica, was funded by Sanofi Genzyme and Regeneron Pharmaceuticals. This research was sponsored by Sanofi and Regeneron Pharmaceuticals (ClinicalTrials.gov Identifier: NCT01920893 ). Medical writing/editorial assistance provided by Sin{\'e}ad Holland, PhD, of Excerpta Medica, was funded by Sanofi Genzyme and Regeneron Pharmaceuticals. Conflicts of interest: T. M. Laidlaw has been a member of national and international scientific advisory boards (consulting) for Allakos, GlaxoSmithKline, Sanofi-Aventis, and Regeneron Pharmaceuticals, Inc. J. Mullol has been a member of national and international scientific advisory boards (consulting) and has received fees for lectures and grants for research projects from ALK-Abell{\'o}, Allakos, FAES, Genentech, Glenmark, GlaxoSmithKline, Mylan, Menarini, MSD, Novartis, Regeneron Pharmaceuticals, Inc, Sanofi Genzyme, UCB, and Uriach. C. Fan, D. Zhang, A. Khan, and L. P. Mannent are employed with Sanofi and may hold stock and/or stock options in the company. N. Amin and J. Chao are employed with Regeneron Pharmaceuticals, Inc, and are shareholders. We thank Qunming Dong for his contribution. This research was sponsored by Sanofi and Regeneron Pharmaceuticals (ClinicalTrials.gov Identifier: NCT01920893 ). Medical writing/editorial assistance provided by Sin{\'e}ad Holland, PhD, of Excerpta Medica, was funded by Sanofi Genzyme and Regeneron Pharmaceuticals. Conflicts of interest: T. M. Laidlaw has been a member of national and international scientific advisory boards (consulting) for Allakos, GlaxoSmithKline, Sanofi-Aventis, and Regeneron Pharmaceuticals, Inc. J. Mullol has been a member of national and international scientific advisory boards (consulting) and has received fees for lectures and grants for research projects from ALK-Abell{\'o}, Allakos, FAES, Genentech, Glenmark, GlaxoSmithKline, Mylan, Menarini, MSD, Novartis, Regeneron Pharmaceuticals, Inc, Sanofi Genzyme, UCB, and Uriach. C. Fan, D. Zhang, A. Khan, and L. P. Mannent are employed with Sanofi and may hold stock and/or stock options in the company. N. Amin and J. Chao are employed with Regeneron Pharmaceuticals, Inc, and are shareholders.",
year = "2019",
month = sep,
day = "1",
doi = "10.1016/j.jaip.2019.03.044",
language = "English",
volume = "7",
pages = "2462--2465.e1",
journal = "Journal of Allergy and Clinical Immunology: In Practice",
issn = "2213-2198",
number = "7",
}